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Conclusions: Sng and Sep plans were very similar from the 
dosimetric (D98, D95, D50, D02) and volumetric (V40) point 
of view. However, in terms of dose delivery (Time, MU), 
differences were remarkable. This may ecologically 
profitable and save patient times. These differences were 
unfluctuating, even if the ROV were changed broadly in the 
clinical situation. 
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Purpose/Objective: To report toxicity considering overall 
treatment time of intensity Modulated Arc Therapy (IMAT) 
with simultaneous integrated boost (SIB) for patients with 
intermediate or high-risk prostate cancer.  
Materials and Methods: One hundred forty two consecutive 
patients, diagnosed with intermediate or high risk prostate 
cancer, were treated definitively between September 2011 
and May 2014. Androgen suppression was administered 
considering disease risk factors. The IMAT plans were 
designed to deliver 70.8 Gy in 30 fractions (2.36 Gy/fraction) 
while delivering simultaneously to the prostate plus margin 
60 Gy (2Gy/fraction).Univariate and multivariate analysis 
with logistic regression were performed looking for relations 
among patient characteristics and toxicity. CTCAE v3.0 
morbidity scores were used to assess acute and late 
toxicities. Outcome, measurements: toxicity and biochemical 
response were assessed prospectively. 
Results: Median age of those patients was 72 years old (from 
58 to 81). Pathologically centralized Gleason score was 7 for 
81.7 % of patients. Mean PSA value was 9.6 ng/ml (from 2 to 
36ng/ml). Forty one percent of patients were classified as 
T1-T2a, 37.5% as T2b-c and 21.5% as T3. Median IPPS was 5 (0 
to15). The median follow-up period was 14.8 months. All 
patients received the prescribed dose in 30 fractions 
delivered between 36 to 57days. Median radiation overall 
treatment time (OTT) was 47 days. Seventy-five percent of 
patients received a course of hormone deprivation for 6 
months at least. One biochemical relapse was observed in 
this cohort of patients. Five patients died during the follow-
up period without cancer relapse or toxicity. Acute genito-
urinary toxicity was observed in 81% of patients with maximal 
score of 2 in 40.9% of patients. Rectal acute toxicity grade 2 
with mucosal discharge was present in 17.6%. Presence of any 
acute rectal toxicity risk is increased by 2.3 fold in the 
shorter OTT. Late rectal toxicity Grade 3 was seen in one 
patient and 5 more patients showed grade 2 score. Chronic 
urinary toxicity grades 1-2 were observed in 27.5% of 
patients, but only two patients with grade 2. Absence of 
acute toxicities decreased the risk for chronic rectal toxicity 
by 0.2 and urinary by 0.09. Neither, hormonal deprivation nor 
fiducial markers for IGRT showed any impact on toxicity. 
Presence of any acute rectal toxicity risk is increased by 2.3 
fold in the shorter OTT. Initial IPSS increased 1.2 fold the risk 
to present any grade of late the urinary toxicity.  
Conclusions: IMAT with SIB to the prostate was well 
tolerated in this series, with acceptable rates of acute and 
early late toxicity. Shorter OTT seems to increase the risk of 
acute rectal toxicity whereas initial IPSS increased the risk of 
late urinary toxicity. The absence of both acute rectal and 
urinary toxicities decreased the risk of chronic toxicities. 
Additional follow-up is necessary to fully define the long-
term toxicity.  
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Purpose/Objective: We initiated a correlative analysis of 
urinary toxicity (UT) and radiation-induced lymphopenia to 
test the hypothesis that patients (pts) experiencing more 
severe lymphopenia may be at higher risk for UT, owing to 
